Type 1 diabetes mellitus: Prevention and disease-modifying therapy - UpToDate

One hundred years after its first clinical use, insulin remains the primary treatment for type 1 diabetes mellitus, but it does not modify the underlying autoimmune process. Furthermore, despite the advent of more physiologic insulin analogs, continuous glucose monitoring, and automated insulin delivery methods, most individuals living with type 1 diabetes do not meet the therapeutic targets that are associated with a lower risk of long-term complications [1,2]. Type 1 diabetes management is expensive, complicated, and exacts a mental and emotional toll on individuals with diabetes and their loved ones [3-6]. Therefore, alternative approaches that modify the natural history of type 1 diabetes, rather than solely treat hyperglycemia, could dramatically improve both quality of life and health outcomes for individuals with type 1 diabetes. This topic will review strategies to prevent or delay clinical type 1 diabetes during preclinical stages of disease, as well as strategies to preserve

One hundred years after its first clinical use, insulin remains the primary treatment for type 1 diabetes mellitus, but it does not modify the underlying autoimmune process. Furthermore, despite the advent of more physiologic insulin analogs, continuous glucose monitoring, and automated insulin delivery methods, most individuals living with type 1 diabetes do not meet the therapeutic targets that are associated with a lower risk of long-term complications [1,2]. Type 1 diabetes management is expensive, complicated, and exacts a mental and emotional toll on individuals with diabetes and their l